Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Added Cholesterol Clear all

Conditions: Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Interventions: VERVE-102, Placebo; Drug
Lead sponsor: Verve Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: DeSoto, Texas

Conditions: Hypercholesterolemia, Familial
Interventions: ISIS 301012; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more

Conditions: Cholesterol
Interventions: Added Cholesterol, No Added Cholesterol; Dietary Supplement · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Type 2 Diabetes Mellitus
Interventions: Low Glycemic Diet, Control Diet; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 35 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Dyslipidemia
Interventions: Atorvastatin, ABT335, ER Niacin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise; Drug · Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 60 Years to 85 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more

Conditions: Hyperlipidemia
Interventions: ETC-1002, Atorvastatin, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Anaheim, California • Los Angeles, California • Northridge, California + 16 more

Conditions: Hypercholesterolemia, Familial
Interventions: ISIS 301012 or Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Chicago, Illinois • Auburn, Maine • Scarborough, Maine + 4 more

Conditions: Cardiovascular Disease, Diabetes
Interventions: Tailored cardiovascular risk management (Nurse-administered ); Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Coronary Heart Disease, Myocardial Infarction
Interventions: Titration of medications, Lifestyle Counseling, Medication Counseling, Usual Care with Medication Reconciliation; Other · Behavioral
Lead sponsor: Middle Tennessee Research Institute; Other
Eligibility: 60 Years to 90 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy Participants, Dyslipidemia
Interventions: AZD4954, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more

Conditions: Hyperlipidemia
Interventions: MCT oil + Butter in Coffee; Dietary Supplement
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: LDL Cholesterol
Interventions: LIB003; Biological
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 5
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Cincinnati, Ohio

Conditions: Coronary Artery Disease
Interventions: Medical/Behavioral therapy, Standard of Care, Registry; Other
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia

Conditions: Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
Interventions: VERVE-102; Drug
Lead sponsor: Verve Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Dothan, Alabama • Pomona, California • Boca Raton, Florida + 7 more

Conditions: Cardiovascular Disease
Interventions: Healthy American Control Diet, Dark Chocolate/Cocoa Diet, Almond Diet, Dark Chocolate/Cocoa + Almond Diet; Other
Lead sponsor: Penn State University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Food Insecurity
Interventions: Food Security Screening & Referral Program; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 5 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Dyslipidemia
Interventions: Evolocumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 27,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 326
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more

Conditions: Hypercholesterolemia, Coronary Heart Disease
Interventions: Different amount of phytosterols are added into diets; Dietary Supplement
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Niemann-Pick Disease, Type C
Interventions: N-Acetyl Cysteine; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 12 Months and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 1
Interventions: Dietary intervention; Behavioral
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pre-Diabetes
Interventions: Functional Ingredient Group, Control Ingredient Group; Dietary Supplement
Lead sponsor: University of Manitoba; Other
Eligibility: 21 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypercholesterolemia
Interventions: bempedoic acid 180mg, placebo, evolocumab; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Type 2 Diabetes
Interventions: Statin, PCSK9 inhibitor, Ezetimibe 10mg; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Dietary Cholesterol and Adipose Tissue Inflammation

Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

Risk Reduction for Alzheimer's Disease

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Cholesterol, Hypertension and Glucose Education Study

Monitoring and Adjustment of Medication Therapy for Patients With Heart Disease

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

Effect of Butter & MCT Oil on Lipoproteins - A RCT

Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

The Precision CAD Trial

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Effects of Polyphenolic-rich Dark Chocolate/Cocoa and Almonds on Cardiovascular Disease Risk Factors

Implementing Food Referrals for Equity and Sustained Health

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Addition of Phytosterols to a Low Phytosterol Diet

Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine

Effect of a Dietary Intervention on Insulin Requirements in Type 1 Diabetes

Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes